Skip to main content

Table 1 Breakpoints

From: Comparative activity of carbapenem testing (the COMPACT study) in Turkey

Family/Genus (species)

FDA

CLSI

EUCAST

 

Doripenem

Imipenem/Meropenem

Doripenem/Imipenem/Meropenem*

Doripenem

Imipenem

Meropenem

 

S

I

R

S

I

R

S

I

R

S

I

R

S

I

R

S

I

R

Pseudomonas aeruginosa

≤ 2

-

-

≤ 4

8

≥ 16

≤ 4

8

≥ 16

≤ 1

2-4

≥ 8

≤ 4

8

≥ 16

≤ 2

4-8

≥ 16

Enterobacteriaceae

≤ 0.5

-

-

≤ 4

8

≥ 16

≤ 1

2

≥ 4

≤ 1

2-4

≥ 8

≤ 2

4-8

≥ 16

≤ 2

4-8

≥ 16

Acinetobacter spp.

≤ 1

-

-

≤ 4

8

≥ 16

≤ 4

8

≥ 16

≤ 1

2-4

≥ 8

≤ 2

4-8

≥ 16

≤ 2

4-8

≥ 16

  1. FDA US Food and Drug Administration; CLSI Clinical and Laboratory Standards Institute; EUCAST European Committee on Antimicrobial Susceptibility Testing; S susceptible; I intermediate; R resistant
  2. *As of June 2010
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us